gliclazide and Cardiovascular Diseases studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.

Research Excerpts

Excerpt	Relevance	Reference
"High blood glucose level, lipid profile disturbances and plasma homocysteine (Hcy) are important risk factors for cardiovascular diseases in patients with type 2 diabetes."	5.20	Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. ( Abd-Allah, GM; Hassan, MH, 2015)
"As compared with the patients receiving insulin monotherapy, the patients taking metformin alone or in combination showed a more effective recovery of carbohydrate and lipid metabolic disturbances, diminished insulin resistance (IR), lowered blood pressure and albuminuria, reduced diastolic dysfunction, and a smaller cardiovascular risk."	5.14	[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. ( Elsukova, OS; Onuchin, SG; Onuchina, EL; Solov'ev, OV, 2010)
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs."	4.90	Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014)
"Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009."	3.81	Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015)
"Treatment with glibenclamide could be associated with higher mortality for cardiovascular diseases and malignancies, in comparison with gliclazide."	3.74	Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. ( Balzi, D; Barchielli, A; Buiatti, E; Lamanna, C; Mannucci, E; Marchionni, N; Masotti, G; Monami, M, 2007)
"Weight loss is strongly recommended for overweight and obese adults with type 2 diabetes."	2.94	The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. ( Chalmers, J; Hamet, P; Harrap, S; Lee, AK; Marre, M; Mcevoy, JW; Ohkuma, T; Selvin, E; Sharrett, AR; Wang, D; Warren, B; Williams, B; Woodward, M, 2020)
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes."	2.75	Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010)
"In this cohort of men with type 2 diabetes, ED was associated with a range of CVD events."	2.75	Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. ( Batty, GD; Chalmers, J; Czernichow, S; de Galan, BE; Hamet, P; Harrap, SB; Huxley, R; Li, Q; Neal, B; Patel, A; Poulter, N; Woodward, M; Zoungas, S, 2010)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."	2.73	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"The primary aim must be the treatment of the insulin resistance."	2.43	[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. ( Schumm-Draeger, PM, 2005)
"Gliclazide is a second-generation sulfonylurea that is widely used in the treatment of non-insulin-dependent diabetes mellitus (NIDDM)."	2.38	Gliclazide: metabolic and vascular effects--a perspective. ( Alberti, KG; Johnson, AB; Taylor, R, 1992)
"A post hoc analysis of patients with type 2 diabetes followed by the ADVANCE-ON (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation - Observational Study)."	1.72	Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. ( Chalmers, J; Hamet, P; Harrap, S; Harris, K; Mancia, G; Poulter, N; Rodgers, A; Wang, N; Williams, B; Woodward, M; Zoungas, S, 2022)
"Glimepiride was associated with the best clinical outcome, showing the lowest mortality and lowest cardiovascular event risk of the five insulin secretagogues."	1.51	Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. ( Huang, HK; Yeh, JI, 2019)
"The objective of this study was to determine if there is a dose-response relationship between sulfonylureas and major adverse cardiovascular events (MACE)."	1.43	Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. ( Abdelmoneim, AS; Eurich, DT; Qiu, W; Senthilselvan, A; Simpson, SH, 2016)
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."	1.43	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016)
"In older patients with type 2 diabetes hospitalized for IHD, prior use of gliclazide, glyburide, or repaglinide appears to be associated with a similar risk of adverse cardiovascular sequelae."	1.42	Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. ( Abdelmoneim, AS; Huang, Y; Light, P; Qiu, W; Simpson, SH, 2015)
"gliclazide treatment."	1.35	Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. ( Khalangot, M; Kovtun, V; Kravchenko, V; Tronko, M, 2009)

Research

Studies (33)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (9.09)	18.2507
2000's	8 (24.24)	29.6817
2010's	18 (54.55)	24.3611
2020's	4 (12.12)	2.80

Authors	Studies
Wang, N	1
Harris, K	1
Hamet, P	5
Harrap, S	5
Mancia, G	4
Poulter, N	7
Williams, B	3
Zoungas, S	7
Woodward, M	9
Chalmers, J	9
Rodgers, A	2
Kalra, S	1
Lee, AK	1
Wang, D	1
Ohkuma, T	2
Warren, B	1
Sharrett, AR	1
Marre, M	4
Mcevoy, JW	1
Selvin, E	1
Tian, J	1
Cooper, M	3
Wang, JG	1
Douros, A	1
Yin, H	1
Yu, OHY	1
Filion, KB	1
Azoulay, L	1
Suissa, S	1
Huang, HK	1
Yeh, JI	1
Bo, S	1
Castiglione, A	1
Ghigo, E	1
Gentile, L	1
Durazzo, M	1
Cavallo-Perin, P	1
Ciccone, G	1
Konig, M	1
Lamos, EM	1
Stein, SA	1
Davis, SN	1
Landman, GW	1
de Bock, GH	1
van Hateren, KJ	1
van Dijk, PR	1
Groenier, KH	1
Gans, RO	1
Houweling, ST	1
Bilo, HJ	1
Kleefstra, N	1
Erem, C	1
Ozbas, HM	1
Nuhoglu, I	1
Deger, O	1
Civan, N	1
Ersoz, HO	1
van der Leeuw, J	2
Visseren, FL	2
Kengne, AP	3
van der Graaf, Y	2
Glasziou, P	2
MacMahon, S	3
Grobbee, DE	3
Mogensen, UM	1
Andersson, C	1
Fosbøl, EL	1
Schramm, TK	1
Vaag, A	1
Scheller, NM	1
Torp-Pedersen, C	1
Gislason, G	1
Køber, L	1
Huang, Y	1
Abdelmoneim, AS	3
Light, P	1
Qiu, W	2
Simpson, SH	3
Hassan, MH	1
Abd-Allah, GM	1
Hirakawa, Y	1
Matthews, DR	1
Patel, A	4
Grobbee, R	1
Jardine, M	1
Eurich, DT	1
Senthilselvan, A	1
Heller, S	3
Neal, B	3
Billot, L	2
Grobbee, D	1
Liu, L	1
Mogensen, CE	1
Pan, C	1
Bompoint, S	1
de Galan, BE	3
Joshi, R	1
Travert, F	1
Khalangot, M	1
Tronko, M	1
Kravchenko, V	1
Kovtun, V	1
Kassem, SA	1
Raz, I	1
Onuchin, SG	1
Elsukova, OS	1
Solov'ev, OV	1
Onuchina, EL	1
Bloomgarden, Z	1
Li, Q	2
Ninomiya, T	1
Batty, GD	1
Czernichow, S	1
Huxley, R	1
Harrap, SB	1
Hasenbank, SE	1
Seubert, JM	1
Brocks, DR	1
Light, PE	1
Avogaro, A	1
Khan, M	1
Xu, Y	1
Edwards, G	1
Urquhart, R	1
Mariz, S	1
Schumm-Draeger, PM	1
Betteridge, DJ	1
Vergès, B	1
Monami, M	1
Balzi, D	1
Lamanna, C	1
Barchielli, A	1
Masotti, G	1
Buiatti, E	1
Marchionni, N	1
Mannucci, E	1
Page, RC	1
Harnden, KE	1
Walravens, NK	1
Onslow, C	1
Sutton, P	1
Levy, JC	1
Hockaday, DT	1
Turner, RC	1
Cathelineau, G	1
de Champvallins, M	1
Bouallouche, A	1
Lesobre, B	1
Alberti, KG	1
Johnson, AB	1
Taylor, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]		8,494 participants (Actual)	Observational	2010-01-31	Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]	Phase 3	11,140 participants (Actual)	Interventional	2001-06-30	Completed
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]		200 participants (Anticipated)	Observational	2012-01-31	Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]		160 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]	Phase 4	135 participants (Actual)	Interventional	2016-10-31	Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]	Phase 3	104 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]		465 participants (Actual)	Interventional	2015-08-31	Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]		150 participants (Anticipated)	Interventional	2016-11-30	Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]	Phase 2	20 participants (Actual)	Interventional	2014-04-30	Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]	Phase 4	60 participants (Actual)	Interventional	2012-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	kg (Mean)
Insulin Glargine, Metformin, Exenatide	-4.8
Insulin Glargine, Metformin, Prandial Insulin	0.7

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	µg/ml (Median)
Sitagliptin	0
Gliclazide	8.4

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmol/L (Median)
Sitagliptin	-0.2
Gliclazide	-0.1

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmHg (Median)
Sitagliptin	4
Gliclazide	-9

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	mmol/L (Median)
Sitagliptin	0.1
Gliclazide	-0.1

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	score on a scale (Median)
Sitagliptin	3
Gliclazide	1.8

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	score on a scale (Median)
Sitagliptin	9.5
Gliclazide	9.4

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Intervention	kg (Median)
Sitagliptin	-0.5
Gliclazide	-0.6

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

Intervention	dCt (Median)
Gliclazide	-1.12
Sitagliptin	0

Intervention	dCt (Median)
Sitagliptin	3.41
Gliclazide	2.09

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

Intervention	pg/ml (Median)
Sitagliptin	-0.07
Gliclazide	0.43

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	Participants (Count of Participants)
Sitagliptin	6
Gliclazide	10

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

Intervention	score on a scale (Median)
	DLQI	HAQ-8	HADS Anxiety	HADS Depression	EQ-5D
Gliclazide	-1.0	0.0	0	0	-0.2
Sitagliptin	0.0	0.0	-1	0	0

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

Article	Year
An insight into the recent diabetes trials: what is the best approach to prevent macrovascular and microvascular complications? Current diabetes reviews, 2013, Volume: 9, Issue:5 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ	2013
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PloS one, 2014, Volume: 9, Issue:2 Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2	2014
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes care, 2009, Volume: 32 Suppl 2 Topics: Administration, Oral; Cardiovascular Diseases; Diabetic Angiopathies; Disease Progression; Enzyme In	2009
Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:2 Topics: Animals; ATP-Binding Cassette Transporters; Carbamates; Cardiovascular Diseases; Cricetinae; Cyclohe	2012
Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes, obesity & metabolism, 2012, Volume: 14 Suppl 1 Topics: Antioxidants; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Ne	2012
[Controversial therapeutic strategies in the treatment of type 2 diabetes mellitus]. MMW Fortschritte der Medizin, 2005, Apr-28, Volume: 147, Issue:17 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Follow-Up Studies; Gli	2005
Gliclazide: metabolic and vascular effects--a perspective. Metabolism: clinical and experimental, 1992, Volume: 41, Issue:5 Suppl 1 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gliclazide; Humans; Insul	1992

Article	Year
The Risks of Cardiovascular Disease and Mortality Following Weight Change in Adults with Diabetes: Results from ADVANCE. The Journal of clinical endocrinology and metabolism, 2020, 01-01, Volume: 105, Issue:1 Topics: Adult; Aged; Body-Weight Trajectory; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combin	2020
Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A Diabetes care, 2020, Volume: 43, Issue:6 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus, Type 2	2020
Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2014, Volume: 122, Issue:5 Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypogly	2014
Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation. Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:1 Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mell	2015
Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus. Pakistan journal of pharmaceutical sciences, 2015, Volume: 28, Issue:5 Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combin	2015
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
[Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus]. Terapevticheskii arkhiv, 2010, Volume: 82, Issue:8 Topics: Blood Glucose; Carbohydrate Metabolism; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug The	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial. Journal of the American College of Cardiology, 2010, Nov-30, Volume: 56, Issue:23 Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Delayed-A	2010
Effects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studies. International journal of clinical practice, 2004, Volume: 58, Issue:10 Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;	2004
Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia, 2005, Volume: 48, Issue:12 Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2;	2005
'Healthy living' and sulphonylurea therapy have different effects on glucose tolerance and risk factors for vascular disease in subjects with impaired glucose tolerance. The Quarterly journal of medicine, 1993, Volume: 86, Issue:3 Topics: Adolescent; Adult; Body Weight; Cardiovascular Diseases; Double-Blind Method; Exercise Therapy; Glic	1993
Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1 Topics: Aged; Albuminuria; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Protocols; Cohort St	1997

Article	Year
Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. Journal of the American College of Cardiology, 2022, 09-20, Volume: 80, Issue:12 Topics: Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Heart Disease Risk F	2022
ADVANCE to ADVANCE-ON: Unfolding the "Legacy Story" in Diabetes. The Journal of the Association of Physicians of India, 2023, Volume: 71, Issue:8 Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Gliclazide; Humans; Insulin; Prospective Studies	2023
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes care, 2017, Volume: 40, Issue:11 Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus	2017
Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis. Diabetes research and clinical practice, 2019, Volume: 152 Topics: Aged; Carbamates; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angio	2019
Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. European journal of endocrinology, 2013, Volume: 169, Issue:1 Topics: Adult; Aged; Cardiovascular Diseases; Cause of Death; Cohort Studies; Confounding Factors, Epidemiol	2013
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. Diabetes research and clinical practice, 2015, Volume: 107, Issue:1 Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina	2015
Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. Journal of diabetes and its complications, 2015, Volume: 29, Issue:2 Topics: Aged; Aged, 80 and over; Alberta; Blue Cross Blue Shield Insurance Plans; Carbamates; Cardiovascular	2015
Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:3 Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopat	2016
Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. Pharmacoepidemiology and drug safety, 2016, Volume: 25, Issue:10 Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Re	2016
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, Volume: 59, Issue:12 Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations	2016
Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes research and clinical practice, 2009, Volume: 86, Issue:3 Topics: Blood Glucose; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Cross-Secti	2009
Recent cardiovascular trials: what are the drivers of benefit and adverse effect? Journal of diabetes, 2009, Volume: 1, Issue:4 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemog	2009
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes/metabolism research and reviews, 2007, Volume: 23, Issue:6 Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies;	2007

gliclazide and Cardiovascular Diseases